Competing interests
Pierre, NB
ONCOLOGY
JD has received consulting or advisory fees from Amgen, Bayer, BeiGene, Eisai, and Pierre Fabre; research grants from AstraZeneca/Medimmune, BeiGene, Bionomics, Bristol-Myers Squibb, GlaxoSmithKline, Lilly, Novartis and Roche. PF has received honoraria for advisory board for MSD and travel grant from Pfizer. VM has received consulting fees from Roche, Bayer, BMS, Janssen and Basilea. SF received financial/honoraria from Akesobio, Amgen, and MSD and has non-financial relationships with Akesobio, Ambrax, Amgen, AstraZeneca, Beigene, Daiichi Sanjyo, Takeda, HaiHe Biopharma, Aulos, Edison Oncology, MSD, ISOFOL, Vivace and WMS. TM has received advisory fees from Bristol-Myers Squibb, MSD and AstraZeneca. BM has received advisory fees from Amgen, Bristol-Myers Squibb, Merck and BeiGene. MV has received honoraria from MSD; and advisory fees from AstraZeneca. TR is an employee of BeiGene and has no competing interests. NB is an employee of BeiGene and has no competing interests. JW is an employee of BeiGene and has no competing interests. JM is an employee of BeiGene and has no competing interests. SY is an employee of BeiGene and has no competing interests. EC has been a consultant or had an advisory role at Adcendo, Alkermes, Amcure, Amunix, Anaveon, AstraZeneca/MedImmune, BeiGene, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharma, Janssen-Cilag, MonTa, MedSIR, MSD Oncology, Nanobiotix, Nouscom, Novartis, OncoDNA, Roche/Genentech, PharmaMar, PsiOxus Therapeutics, Sanofi, Seattle Genetics, Servier, Syneos Health, TargImmune, T-Knife and research grants from Achilles, BeiGene, START. JM-L has received lecture fees from Astellas, Bristol-Myers Squibb, MSD, Novartis, Pierre Fabre, Pfizer, Roche and Sanofi; advisory fees from Bristol-Myers Squibb, Highlight Therapeutics, Novartis, Pierre Fabre, Roche and Sanofi; research grants from Sanofi; and travel grants from Bristol-Myers Squibb, MSD, Novartis, Pierre Fabre, Pfizer, Roche and Ipsen.